- Report
- March 2024
- 117 Pages
Global
From €4317EUR$4,500USD£3,708GBP
- Report
- January 2024
- 269 Pages
Global
From €6604EUR$7,125USD£5,481GBP
- Report
- March 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- February 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- January 2024
- 144 Pages
Global
From €3740EUR$3,899USD£3,213GBP
- Report
- April 2023
- 175 Pages
Global
From €5659EUR$5,899USD£4,861GBP
- Report
- January 2023
- 50 Pages
China
From €2878EUR$3,000USD£2,472GBP
- Report
- January 2021
- 145 Pages
China, Global
From €3000EUR$3,350USD£2,667GBP
- Report
- January 2024
- 83 Pages
Global
From €3500EUR$3,908USD£3,112GBP
- Report
- October 2023
- 270 Pages
China
From €3837EUR$4,000USD£3,296GBP
- Report
- October 2023
- 135 Pages
China
From €1727EUR$1,800USD£1,483GBP
Ceftriaxone is an antibiotic used to treat a wide range of bacterial infections. It belongs to the cephalosporin class of antibiotics, which are used to treat infections caused by Gram-positive and Gram-negative bacteria. Ceftriaxone is commonly used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. It is also used to treat meningitis, sepsis, and gonorrhea. Ceftriaxone is available in both intravenous and intramuscular forms, and is often used in combination with other antibiotics.
The ceftriaxone market is driven by the increasing prevalence of bacterial infections, the growing demand for antibiotics, and the increasing availability of generic versions of the drug. The market is also driven by the increasing use of ceftriaxone in the treatment of multi-drug resistant infections.
Some of the major companies in the ceftriaxone market include Pfizer, Merck, GlaxoSmithKline, Sanofi, Novartis, and AstraZeneca. Show Less Read more